Literature DB >> 19695299

No correlation between time-linked plasma and CSF Abeta levels.

Nathalie Le Bastard1, Laetitia Aerts, Judith Leurs, Walter Blomme, Peter P De Deyn, Sebastiaan Engelborghs.   

Abstract

Plasma beta-amyloid protein (Abeta) isoforms are considered potential biomarkers for Alzheimer's disease (AD) and dementia. The relation between plasma and cerebrospinal fluid (CSF) levels of Abeta isoforms remains unclear. In order to identify possible correlations between Abeta levels in plasma and CSF we determined Abeta levels in time-linked plasma and CSF samples. Abeta concentrations in plasma (Abeta(1-42) and Abeta(N-42)) and CSF (Abeta(1-42)) samples from 49 AD patients, 47 non-Alzheimer's disease dementia (NONAD) patients, 39 MCI patients and 29 controls were determined using a multi-parameter fluorimetric bead-based immunoassay using xMAP((R)) technology (for plasma) and a conventional single-parameter ELISA (for CSF). Plasma Abeta(1-42) concentrations did not correlate with CSF Abeta(1-42) concentrations in the total study population, or in the different diagnostic groups. No correlations between plasma Abeta(N-42) and CSF Abeta(1-42) levels were found either. The CSF/serum albumin index did not show any significant differences between AD, NONAD, MCI and controls. These results suggest that the Abeta levels in plasma are independent of the Abeta levels in CSF both in dementia and controls. The fact that CSF and plasma Abeta do not correlate in patients as well as controls and no significant differences in plasma Abeta(1-42) or Abeta(N-42) between patients and controls can be detected hampers the diagnostic utility of the plasma Abeta levels as biomarkers for dementia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695299     DOI: 10.1016/j.neuint.2009.08.006

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  20 in total

1.  Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Authors:  N Schupf; W B Zigman; M-X Tang; D Pang; R Mayeux; P Mehta; W Silverman
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

2.  Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.

Authors:  D P Devanand; N Schupf; Y Stern; R Parsey; G H Pelton; P Mehta; R Mayeux
Journal:  Neurology       Date:  2011-06-29       Impact factor: 9.910

3.  Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.

Authors:  Qing-Hui Zhou; Ailing Fu; Ruben J Boado; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  Mol Pharm       Date:  2010-12-21       Impact factor: 4.939

4.  Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease.

Authors:  Yannick Vermeiren; Nathalie Le Bastard; Christopher M Clark; Sebastiaan Engelborghs; Peter P De Deyn
Journal:  Neurochem Res       Date:  2011-05-20       Impact factor: 3.996

5.  Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.

Authors:  Maria Bjerke; Erik Portelius; Lennart Minthon; Anders Wallin; Henrik Anckarsäter; Rolf Anckarsäter; Niels Andreasen; Henrik Zetterberg; Ulf Andreasson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-15

Review 6.  Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress.

Authors:  Ashvini Keshavan; Amanda Heslegrave; Henrik Zetterberg; Jonathan M Schott
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

7.  Detection of retinal and blood Aβ oligomers with nanobodies.

Authors:  Umma Habiba; Joseph Descallar; Fabian Kreilaus; Utpal K Adhikari; Sachin Kumar; John W Morley; Bang V Bui; Maya Koronyo-Hamaoui; Mourad Tayebi
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-06

Review 8.  Oxidative Stress and Its Clinical Applications in Dementia.

Authors:  Peizhong Mao
Journal:  J Neurodegener Dis       Date:  2012-08-30

Review 9.  Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology.

Authors:  Alison L Baird; Sarah Westwood; Simon Lovestone
Journal:  Front Neurol       Date:  2015-11-16       Impact factor: 4.003

Review 10.  Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker.

Authors:  Jon B Toledo; Leslie M Shaw; John Q Trojanowski
Journal:  Alzheimers Res Ther       Date:  2013-03-08       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.